Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INCYTE CORPINCY · Entity 3182 | Director · Chief Executive Officer | July 16, 2026 | July 20, 2026 |
| Syndax Pharmaceuticals IncSNDX · Entity 4578 | Director | February 05, 2025 | February 07, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INCYTE CORP
Report date July 16, 2026 · Filed July 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 183,129 |
Reported balance
After 2026-07-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-16 · Grant · Acquired 26,807 · Balance 183,129 F1: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2: Including the July 16, 2026 grant, this includes an aggregate of 178,883 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2029-07-16 | Direct | 80,421 |
Reported balance
After 2026-07-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-16 · Grant · Acquired 80,421 · Balance 80,421 F3: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $116.65 · Expires 2036-07-15 | Direct | 77,148 |
Reported balance
After 2026-07-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-16 · Grant · Acquired 77,148 · Balance 77,148 F4: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks: |
Filing footnotes · ownership attribution and instrument terms
F1: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.
F2: Including the July 16, 2026 grant, this includes an aggregate of 178,883 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.
F3: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.
F4: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks:
Syndax Pharmaceuticals Inc
Report date February 05, 2025 · Filed February 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 90,000 |
Reported balance
After 2025-02-05 transaction · row 1
1 source rowRow 1 · 2025-02-05 · Grant · Acquired 25,000 · Balance 90,000 F1: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Allergan plc
Report date May 08, 2020 · Filed May 12, 2020
Section 16 reporting ended · disclosed 2020-05-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value $0.0001SEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-05-08 · Disposition to issuer · Disposed 7,434 · Balance 0 F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share. |
| Restricted Stock UnitsSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2020-05-08 · Disposition to issuer · Disposed 25,201 · Balance 0 F2: Reflects the disposition of restricted stock units relating to Allergan Shares ("Allergan RSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan RSU was substituted by AbbVie with a corresponding AbbVie restricted stock unit award relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formula set forth in the Transaction Agreement. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $224.00 · Expires 2023-05-08 | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-05-08 · Disposition to issuer · Disposed 19,278 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $63.51 · Expires 2021-12-04 | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-05-08 · Disposition to issuer · Disposed 1 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $72.07 · Expires 2022-05-06 | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-05-08 · Disposition to issuer · Disposed 1,387 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $80.20 · Expires 2023-05-20 | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-05-08 · Disposition to issuer · Disposed 1,246 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $196.16 · Expires 2024-05-12 | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-05-08 · Disposition to issuer · Disposed 509 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $63.51 · Expires 2021-12-04 | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-05-08 · Disposition to issuer · Disposed 16,081 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $72.07 · Expires 2022-05-06 | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-05-08 · Disposition to issuer · Disposed 10,089 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $80.20 · Expires 2023-05-20 | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-05-08 · Disposition to issuer · Disposed 21,621 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $196.16 · Expires 2024-05-12 | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-05-08 · Disposition to issuer · Disposed 12,304 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2020-05-08 · Disposition to issuer · Disposed 26,506 · Balance 0 F5: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target). |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.
F2: Reflects the disposition of restricted stock units relating to Allergan Shares ("Allergan RSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan RSU was substituted by AbbVie with a corresponding AbbVie restricted stock unit award relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formula set forth in the Transaction Agreement.
F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.
F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement.
F5: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target).
Karuna Therapeutics, Inc.
Report date March 18, 2024 · Filed March 18, 2024
Section 16 reporting ended · disclosed 2024-03-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-03-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-03-18 · Disposition to issuer · Disposed 10,342 · Balance 19,037 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. Row 2 · 2024-03-18 · Disposition to issuer · Disposed 19,037 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F3: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-18 · Disposition to issuer · Disposed 38,688 · Balance 0 F4: Represents RSUs granted on February 13, 2024 (the "2024 RSUs"), each representing a contingent right to receive one share of Common Stock, provided that, at the effective time of the Merger, any 2024 RSUs that were not vested and remained outstanding as of such date were cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of unvested 2024 RSUs outstanding at the effective time of the Merger multiplied by (ii) the Merger Consideration (the "Cash Award"). The Cash Award shall vest annually in four equal installments on each of February 13, 2025, February 13, 2026, February 13, 2027 and February 13, 2028, subject to the reporting person's continued service through each such vesting date. F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $193.19 · Expires 2033-01-02 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-03-18 · Disposition to issuer · Disposed 63,065 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options vested as to 25% on January 3, 2024, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers.
F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.
F3: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration.
F4: Represents RSUs granted on February 13, 2024 (the "2024 RSUs"), each representing a contingent right to receive one share of Common Stock, provided that, at the effective time of the Merger, any 2024 RSUs that were not vested and remained outstanding as of such date were cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of unvested 2024 RSUs outstanding at the effective time of the Merger multiplied by (ii) the Merger Consideration (the "Cash Award"). The Cash Award shall vest annually in four equal installments on each of February 13, 2025, February 13, 2026, February 13, 2027 and February 13, 2028, subject to the reporting person's continued service through each such vesting date.
F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option.
F6: These Options vested as to 25% on January 3, 2024, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 25, 2018 Filed Sep 27, 2018 21:42 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $7.11 | $0.00 |
DisclosureSEC source: 0001562180-18-004049 · primarydocument.xml · derivative · entry 1 Meury William · CIK 0001536778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2028-09-25 F1 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest monthly over a three-year period. Read SEC document |
| May 17, 2018 Filed May 21, 2018 21:21 UTC | Allergan plc AGN · Entity 149298 | Exercise / conversionNon-Qualified Options to Purchase Common Stock · Derivative | 19,785 | $0.00 Strike: $68.11 | $0.00 |
DisclosureSEC source: 0001179110-18-007255 · edgar.xml · derivative · entry 5 Meury William · CIK 0001536778 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 19,785 shares Expires 2018-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options vested in five equal installments on December 6, 2011, 2012, 2013, 2014 and 2015. Read SEC document |
| May 17, 2018 Filed May 21, 2018 21:21 UTC | Allergan plc AGN · Entity 149298 | Exercise / conversionIncentive Stock Option · Derivative | 1,467 | $0.00 Strike: $68.11 | $0.00 |
DisclosureSEC source: 0001179110-18-007255 · edgar.xml · derivative · entry 4 Meury William · CIK 0001536778 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,467 shares Expires 2018-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options vested on December 6, 2015. Read SEC document |
| May 17, 2018 Filed May 21, 2018 21:21 UTC | Allergan plc AGN · Entity 149298 | SaleOrdinary Shares, par value $0.0001 | 24,425 | $154.59 | $3,775,860.75 |
DisclosureSEC source: 0001179110-18-007255 · edgar.xml · nonDerivative · entry 3 Meury William · CIK 0001536778 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,729 F3 · shares: This sale is pursuant to a previously established 10b5-1 Trading Plan dated November 16, 2017 for the Reporting Person. F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| May 17, 2018 Filed May 21, 2018 21:21 UTC | Allergan plc AGN · Entity 149298 | Exercise / conversionOrdinary Shares, par value $0.0001 | 19,785 | $68.11 | $1,347,556.35 |
DisclosureSEC source: 0001179110-18-007255 · edgar.xml · nonDerivative · entry 2 Meury William · CIK 0001536778 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This exercise is pursuant to a previously established 10b5-1 Trading Plan dated November 16, 2017 for the Reporting Person. F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| May 17, 2018 Filed May 21, 2018 21:21 UTC | Allergan plc AGN · Entity 149298 | Exercise / conversionOrdinary Shares, par value $0.0001 | 1,467 | $68.11 | $99,917.37 |
DisclosureSEC source: 0001179110-18-007255 · edgar.xml · nonDerivative · entry 1 Meury William · CIK 0001536778 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,369 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This exercise is pursuant to a previously established 10b5-1 Trading Plan dated November 16, 2017 for the Reporting Person. F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 22:57 UTC | Allergan plc AGN · Entity 149298 | Tax withholdingOrdinary Shares, par value $0.0001 | 819 | $164.74 | $134,922.06 |
DisclosureSEC source: 0000903423-18-000200 · meuryf4.xml · nonDerivative · entry 1 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,902 F1 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 22:10 UTC | Allergan plc AGN · Entity 149298 | Exercise / conversionNon-Qualified Options to Purchase Common Stock · Derivative | 17,381 | $0.00 Strike: $66.20 | $0.00 |
DisclosureSEC source: 0001179110-18-002291 · edgar.xml · derivative · entry 17 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 17,381 shares Expires 2019-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F15 · derivative.exercise_date: The option vested in five equal installments on December 7, 2010, 2011, 2012, 2013 and 2014. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 22:10 UTC | Allergan plc AGN · Entity 149298 | Exercise / conversionIncentive Stock Option · Derivative | 1,510 | $0.00 Strike: $66.20 | $0.00 |
DisclosureSEC source: 0001179110-18-002291 · edgar.xml · derivative · entry 16 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,510 shares Expires 2019-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: The option vested on December 7, 2014. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 22:10 UTC | Allergan plc AGN · Entity 149298 | Exercise / conversionNon-Qualified Options to Purchase Common Stock · Derivative | 2,765 | $0.00 Strike: $51.07 | $0.00 |
DisclosureSEC source: 0001179110-18-002291 · edgar.xml · derivative · entry 15 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,765 shares Expires 2018-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: The option vested in five equal installments on December 8, 2009, 2010, 2011, 2012 and 2013. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 22:10 UTC | Allergan plc AGN · Entity 149298 | Exercise / conversionIncentive Stock Option · Derivative | 1,957 | $0.00 Strike: $51.07 | $0.00 |
DisclosureSEC source: 0001179110-18-002291 · edgar.xml · derivative · entry 14 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,957 shares Expires 2018-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The option vested on December 8, 2013. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 22:10 UTC | Allergan plc AGN · Entity 149298 | SaleOrdinary Shares, par value $0.0001 | 13,600 | $165.16 | $2,246,176.00 |
DisclosureSEC source: 0001179110-18-002291 · edgar.xml · nonDerivative · entry 13 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,721 F11 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $165.05 to $165.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 22:10 UTC | Allergan plc AGN · Entity 149298 | SaleOrdinary Shares, par value $0.0001 | 2,000 | $164.62 | $329,240.00 |
DisclosureSEC source: 0001179110-18-002291 · edgar.xml · nonDerivative · entry 12 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,321 F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $164.04 to $165.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 22:10 UTC | Allergan plc AGN · Entity 149298 | SaleOrdinary Shares, par value $0.0001 | 7,200 | $163.04 | $1,173,888.00 |
DisclosureSEC source: 0001179110-18-002291 · edgar.xml · nonDerivative · entry 11 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,321 F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.68 to $163.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 22:10 UTC | Allergan plc AGN · Entity 149298 | SaleOrdinary Shares, par value $0.0001 | 4,700 | $162.22 | $762,434.00 |
DisclosureSEC source: 0001179110-18-002291 · edgar.xml · nonDerivative · entry 10 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,521 F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $161.67 to $162.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 22:10 UTC | Allergan plc AGN · Entity 149298 | SaleOrdinary Shares, par vaule $0.0001 | 1,000 | $161.10 | $161,100.00 |
DisclosureSEC source: 0001179110-18-002291 · edgar.xml · nonDerivative · entry 9 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,221 F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.59 to $161.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 22:10 UTC | Allergan plc AGN · Entity 149298 | SaleOrdinary Shares, par value $0.0001 | 2,400 | $159.82 | $383,568.00 |
DisclosureSEC source: 0001179110-18-002291 · edgar.xml · nonDerivative · entry 8 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,221 F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.41 to $160.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 22:10 UTC | Allergan plc AGN · Entity 149298 | SaleOrdinary Shares, par vaule $0.0001 | 1,700 | $158.78 | $269,926.00 |
DisclosureSEC source: 0001179110-18-002291 · edgar.xml · nonDerivative · entry 7 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,621 F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.30 to $159.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 22:10 UTC | Allergan plc AGN · Entity 149298 | SaleOrdinary Shares, par value $0.0001 | 1,200 | $157.60 | $189,120.00 |
DisclosureSEC source: 0001179110-18-002291 · edgar.xml · nonDerivative · entry 6 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,321 F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.30 to $158.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 22:10 UTC | Allergan plc AGN · Entity 149298 | SaleOrdinary Shares, par value $0.0001 | 25,079 | $157.18 | $3,941,917.22 |
DisclosureSEC source: 0001179110-18-002291 · edgar.xml · nonDerivative · entry 5 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,521 F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.29 to $157.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 22:10 UTC | Allergan plc AGN · Entity 149298 | Exercise / conversionOrdinary Shares, par value $0.0001 | 17,381 | $66.20 | $1,150,622.20 |
DisclosureSEC source: 0001179110-18-002291 · edgar.xml · nonDerivative · entry 4 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 22:10 UTC | Allergan plc AGN · Entity 149298 | Exercise / conversionOrdinary Shares, par value $0.0001 | 1,510 | $66.20 | $99,962.00 |
DisclosureSEC source: 0001179110-18-002291 · edgar.xml · nonDerivative · entry 3 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 22:10 UTC | Allergan plc AGN · Entity 149298 | Exercise / conversionOrdinary Shares, par value $0.0001 | 2,765 | $51.07 | $141,208.55 |
DisclosureSEC source: 0001179110-18-002291 · edgar.xml · nonDerivative · entry 2 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 22:10 UTC | Allergan plc AGN · Entity 149298 | Exercise / conversionOrdinary Shares, par value $0.0001 | 1,957 | $51.07 | $99,943.99 |
DisclosureSEC source: 0001179110-18-002291 · edgar.xml · nonDerivative · entry 1 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The total number of shares reported has been reduced by 423 due to prior inadvertent over-reporting of shares beneficially owned by the Reporting Person. F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 21:41 UTC | Allergan plc AGN · Entity 149298 | Tax withholdingOrdinary Shares, par value $0.0001 | 1,611 | $163.58 | $263,527.38 |
DisclosureSEC source: 0001179110-18-000120 · edgar.xml · nonDerivative · entry 1 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,410 F1 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 23:21 UTC | Allergan plc AGN · Entity 149298 | Exercise / conversionIncentive Stock Option · Derivative | 2,535 | $0.00 Strike: $78.88 | $0.00 |
DisclosureSEC source: 0001179110-17-014859 · edgar.xml · derivative · entry 6 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,535 shares Expires 2017-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested in two equal installments on December 6, 2011 and 2012. Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 23:21 UTC | Allergan plc AGN · Entity 149298 | Exercise / conversionNon-Qualified Options to Purchase Common Stock · Derivative | 9,272 | $0.00 Strike: $78.88 | $0.00 |
DisclosureSEC source: 0001179110-17-014859 · edgar.xml · derivative · entry 5 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,272 shares Expires 2017-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested in five equal installments on December 6, 2008, 2009, 2010, 2011 and 2012. Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 23:21 UTC | Allergan plc AGN · Entity 149298 | SaleOrdinary Shares, par value $0.0001 | 2,535 | $173.89 | $440,811.15 |
DisclosureSEC source: 0001179110-17-014859 · edgar.xml · nonDerivative · entry 4 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,021 F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $173.51to $174.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F4 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 23:21 UTC | Allergan plc AGN · Entity 149298 | SaleOrdinary Shares, par value $0.0001 | 9,272 | $173.89 | $1,612,308.08 |
DisclosureSEC source: 0001179110-17-014859 · edgar.xml · nonDerivative · entry 3 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,556 F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $173.51to $174.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F4 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 23:21 UTC | Allergan plc AGN · Entity 149298 | Exercise / conversionOrdinary Shares, par value $0.0001 | 2,535 | $78.88 | $199,960.80 |
DisclosureSEC source: 0001179110-17-014859 · edgar.xml · nonDerivative · entry 2 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,828 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 23:21 UTC | Allergan plc AGN · Entity 149298 | Exercise / conversionOrdinary Shares, par value $0.0001 | 9,272 | $78.88 | $731,375.36 |
DisclosureSEC source: 0001179110-17-014859 · edgar.xml · nonDerivative · entry 1 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| October 26, 2017 Filed Oct 31, 2017 01:24 UTC | Allergan plc AGN · Entity 149298 | Exercise / conversionPerformance Based Restricted Share Unit · Derivative | 9,321 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-013554 · edgar.xml · derivative · entry 2 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,321 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person. F2 · price: Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person. F2 · derivative.exercise_date: Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person. F2 · derivative.expiration_date: Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person. Read SEC document |
| October 26, 2017 Filed Oct 31, 2017 01:24 UTC | Allergan plc AGN · Entity 149298 | Exercise / conversionOrdinary Shares, par value $0.0001 | 9,321 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-013554 · edgar.xml · nonDerivative · entry 1 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported securities are restricted share units, each of which represents a right to receive one ordinary share of Allergan plc. The restricted share units will vest in equal installments on each of December 31, 2017, December 31, 2018 and December 31, 2019. F2 · price: Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person. F3 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| May 15, 2017 Filed May 16, 2017 22:08 UTC | Allergan plc AGN · Entity 149298 | Tax withholdingOrdinary Shares, par value $0.0001 | 587 | $228.22 | $133,965.14 |
DisclosureSEC source: 0001179110-17-007334 · edgar.xml · nonDerivative · entry 1 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,700 F1 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 20:22 UTC | Allergan plc AGN · Entity 149298 | GrantOrdinary Shares, par value $0.0001 | 8,835 | $237.68 | $2,099,902.80 |
DisclosureSEC source: 0001179110-17-005546 · edgar.xml · nonDerivative · entry 1 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,287 F1 · shares: The reported securities are restricted share units, each of which represents a right to receive one ordinary share of Allergan plc. The restricted share units will vest twenty percent (20%) on April 3, 2018, twenty percent (20%) on April 3, 2019, twenty percent (20%) on April 3, 2020, twenty percent (20%) on April 3, 2021 and twenty percent (20%) on April 3, 2022. F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| December 08, 2016 Filed Feb 15, 2017 02:13 UTC | Allergan plc AGN · Entity 149298 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 11,807 | $0.00 Strike: $188.47 | $0.00 |
DisclosureSEC source: 0001179110-17-002432 · edgar.xml · derivative · entry 3 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 11,807 shares Expires 2016-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2016 Filed Feb 15, 2017 02:13 UTC | Allergan plc AGN · Entity 149298 | Tax withholdingOrdinary Shares, par value $0.0001 | 9,414 | $188.47 | $1,774,256.58 |
DisclosureSEC source: 0001179110-17-002432 · edgar.xml · nonDerivative · entry 2 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,452 F1 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| December 08, 2016 Filed Feb 15, 2017 02:13 UTC | Allergan plc AGN · Entity 149298 | Exercise / conversionOrdinary Shares, par value $0.0001 | 11,807 | $109.12 | $1,288,379.84 |
DisclosureSEC source: 0001179110-17-002432 · edgar.xml · nonDerivative · entry 1 Meury William · CIK 0001536778 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,866 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.